免疫療法薬の市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

免疫療法薬市場は、2023年に1,756億4,000万米ドルと評価され、2024年には1,969億6,000万米ドルに達すると予測され、CAGR 12.35％で成長し、2030年には3,970億2,000万米ドルに達すると予測されています。

免疫療法薬医薬品業界における強力かつ発展的なセグメントである免疫療法は、がん、感染症、その他の疾患と闘う免疫系の能力を強化または変更するように設計されています。免疫療法の必要性は、特定の細胞をより正確に標的にする能力にあり、化学療法のような従来の治療法に比べて副作用が少ない可能性があります。これらの治療薬の用途は、腫瘍学、感染症管理、自己免疫疾患、アレルギー治療など多岐にわたる。最終用途は主に病院、がん研究機関、専門クリニックです。重要な成長要因としては、バイオテクノロジーの進歩、がんや慢性疾患の有病率の上昇、研究開発資金の増加などが挙げられます。個別化医療と併用療法に主な機会が存在し、治療効果を高め、治療耐性を低下させることができます。デジタルヘルス技術の導入や、バイオテクノロジー企業との医薬品共同開発のための提携も、潜在的な市場機会を活用するために推奨される戦略です。しかし、高い開発コスト、厳しい規制当局の承認、免疫反応の複雑さといった課題が、市場拡大を複雑にしています。知的財産の問題や、長期的な影響についての理解が限られていることが、さらに進展の妨げとなっています。イノベーションは、より良い患者層別化のためのバイオマーカーの開発、薬剤の安定性と有効性を高めるデリバリーメカニズムの改善、既存薬剤の適応拡大などに集中することができます。腫瘍の微小環境と免疫のランドスケープを理解するための継続的な調査は、引き続き極めて重要です。市場は、急速な技術進歩、製薬大手間の高い競合、戦略的提携や合併の増加といった特徴を有しています。全体として、この分野の利害関係者は、新たな科学的発見に常に注意を払い、技術統合に柔軟に対応し、免疫療法の可能性を最大限に引き出すために革新的な臨床試験に投資すべきです。

市場力学：急速に進化する免疫療法薬市場の主要市場インサイトを公開

免疫療法薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の慢性疾患罹患率の上昇
  • 新しい免疫療法薬の承認と発売の増加
  • 消費者の間での個別化医療に対する需要の高まり
• 市場抑制要因
  • 複雑で長い承認プロセス
• 市場機会
  • 先進的な免疫療法薬の開発を重視する政府の増加
  • 民間企業や新興バイオベンチャーからの投資の増加
• 市場の課題
  • 医薬品の副作用に関する安全性への懸念の高まり

ポーターの5つの力：免疫療法薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：免疫療法薬市場における外部からの影響の把握

外部マクロ環境要因は、免疫療法薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析免疫療法薬市場における競合情勢の把握

免疫療法薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス免疫療法薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、免疫療法薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨免疫療法薬市場における成功への道筋を描く

免疫療法薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の世界の増加
    • 新しい免疫療法薬の承認と発売の増加
    • 消費者の間でパーソナライズ医療の需要が高まる
  • 抑制要因
    • 複雑で長い承認プロセス
  • 機会
    • 政府は先進的な技術の開発にますます力を入れている
    • 民間セクターと新興バイオテクノロジースタートアップからの投資増加
  • 課題
    • 医薬品の副作用に関する安全性の懸念の高まり
• 市場セグメンテーション分析
  • タイプ：がん罹患率の上昇に伴い、がんワクチンの需要が増加
  • 応用：自己免疫疾患治療への新たな応用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 免疫療法薬の市場：タイプ別

• がんワクチン
• チェックポイント阻害剤
• サイトカイン療法
• モノクローナル抗体
• T細胞療法

第7章 免疫療法薬の市場：用途別

• 自己免疫疾患
• 感染症
• 神経学
• 腫瘍学

第8章 免疫療法薬の市場：エンドユーザー別

• 病院
• 専門クリニック

第9章 南北アメリカの免疫療法薬の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の免疫療法薬の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの免疫療法薬の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ハンミ製薬とメルクが提携し、進行がん治療における相乗的免疫療法の先駆者となる
  • Pathios Therapeuticsは、免疫療法の臨床試験を推進し、長期的な腫瘍学の革新を推進するために、シリーズ Bで2,500万米ドルを確保しました。
  • ファイザーは、先進的なADC技術による革新的ながん治療を加速し、腫瘍学におけるリーダーシップを強化し、世界の影響力を拡大するためにシーゲンを買収しました。
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Affimed Therapeutics
• AstraZeneca PLC
• Atara Biotherapeutics
• Biogen Inc.
• Boston Scientific Corporation
• Bristol-Myers Squibb Company
• CARsgen Therapeutics
• Celldex Therapeutics
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• ElevateBio
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Samyang Holdings Corporation
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Turnstone Biologics

LIST OF FIGURES

• FIGURE 1. IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. IMMUNOTHERAPY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IMMUNOTHERAPY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Immunotherapy Drugs Market was valued at USD 175.64 billion in 2023, expected to reach USD 196.96 billion in 2024, and is projected to grow at a CAGR of 12.35%, to USD 397.02 billion by 2030.

Immunotherapy drugs, a potent and evolving segment in the pharmaceutical industry, are designed to enhance or modify the immune system's ability to fight cancer, infectious diseases, and other disorders. The necessity of immunotherapy lies in its ability to target specific cells more precisely, offering potentially fewer side effects compared to traditional therapies like chemotherapy. Applications of these drugs span oncology, infectious disease management, autoimmune disorders, and allergy treatment. End-use is primarily within hospitals, cancer research institutions, and specialty clinics. Critical growth factors include advancements in biotechnology, rising prevalence of cancer and chronic diseases, and increased funding for research and development. Key opportunities exist in personalized medicine and combination therapies, which can enhance the efficacy and reduce resistance to treatment. Embracing digital health technologies and conducting collaborations for co-developing drugs with biotech firms are also recommended strategies for harnessing potential market opportunities. However, challenges such as high development costs, stringent regulatory approvals, and the complexity of immune responses complicate market expansion. Intellectual property issues and limited understanding of long-term effects further hinder progress. Innovation can be focused on the development of biomarkers for better patient stratification, improving delivery mechanisms to enhance drug stability and effectiveness, and expanding indications for existing drugs. Continuous research into understanding tumor microenvironments and immune landscapes remain pivotal. The market is characterized by rapid technological advancements, high competition among pharmaceutical giants, and an increasing number of strategic partnerships and mergers. Overall, stakeholders in the field should stay vigilant to emerging scientific discoveries, adapt flexibly to technological integrations, and invest in innovative clinical trials to optimize immunotherapy's full potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunotherapy Drugs Market

The Immunotherapy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • The rising incidence of chronic diseases globally
  • Increasing approval and launch of new immunotherapy drugs
  • Growing demand for personalized medicine among consumers
• Market Restraints
  • Complex and lengthy approval processes
• Market Opportunities
  • Growing government emphasis on development of advanced immunotherapy drugs
  • Rising investments from private sectors and emerging biotech startups
• Market Challenges
  • Emerging safety concerns of side effects of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Immunotherapy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunotherapy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunotherapy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunotherapy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunotherapy Drugs Market

A detailed market share analysis in the Immunotherapy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunotherapy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunotherapy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunotherapy Drugs Market

A strategic analysis of the Immunotherapy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunotherapy Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Affimed Therapeutics, AstraZeneca PLC, Atara Biotherapeutics, Biogen Inc., Boston Scientific Corporation, Bristol-Myers Squibb Company, CARsgen Therapeutics, Celldex Therapeutics, Cipla Ltd., Dr. Reddy's Laboratories Ltd., ElevateBio, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Samyang Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Turnstone Biologics.

Market Segmentation & Coverage

This research report categorizes the Immunotherapy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Cancer Vaccines, Checkpoint Inhibitors, Cytokines-Based Therapy, Monoclonal Antibodies, and T-cell Therapy.
• Based on Application, market is studied across Autoimmune Disease, Infectious Disease, Neurology, and Oncology.
• Based on End-User, market is studied across Hospitals and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. The rising incidence of chronic diseases globally
    • 5.1.1.2. Increasing approval and launch of new immunotherapy drugs
    • 5.1.1.3. Growing demand for personalized medicine among consumers
  • 5.1.2. Restraints
    • 5.1.2.1. Complex and lengthy approval processes
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing government emphasis on development of advanced immunotherapy drugs
    • 5.1.3.2. Rising investments from private sectors and emerging biotech startups
  • 5.1.4. Challenges
    • 5.1.4.1. Emerging safety concerns of side effects of drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing demand for cancer vaccines with the rising prevalence of cancer
  • 5.2.2. Application: Emerging application for autoimmune disease therapy
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Immunotherapy Drugs Market, by Type

• 6.1. Introduction
• 6.2. Cancer Vaccines
• 6.3. Checkpoint Inhibitors
• 6.4. Cytokines-Based Therapy
• 6.5. Monoclonal Antibodies
• 6.6. T-cell Therapy

7. Immunotherapy Drugs Market, by Application

• 7.1. Introduction
• 7.2. Autoimmune Disease
• 7.3. Infectious Disease
• 7.4. Neurology
• 7.5. Oncology

8. Immunotherapy Drugs Market, by End-User

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Specialty Clinics

9. Americas Immunotherapy Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Immunotherapy Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Immunotherapy Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Hanmi Pharmaceutical and Merck forge partnership to pioneer synergistic immunotherapy for advanced cancer treatment
  • 12.3.2. Pathios Therapeutics secures USD 25 Million in series B to propel immunotherapy treatments into clinical trials and drive long-term oncology innovations
  • 12.3.3. Pfizer acquires Seagen to accelerate innovative cancer therapies with advanced ADC technology, strengthening leadership in oncology and expanding global impact
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Affimed Therapeutics
• 3. AstraZeneca PLC
• 4. Atara Biotherapeutics
• 5. Biogen Inc.
• 6. Boston Scientific Corporation
• 7. Bristol-Myers Squibb Company
• 8. CARsgen Therapeutics
• 9. Celldex Therapeutics
• 10. Cipla Ltd.
• 11. Dr. Reddy's Laboratories Ltd.
• 12. ElevateBio
• 13. F. Hoffmann-La Roche AG
• 14. Gilead Sciences, Inc.
• 15. GlaxoSmithKline PLC
• 16. Johnson & Johnson Services, Inc.
• 17. Merck & Co., Inc.
• 18. Novartis AG
• 19. Pfizer Inc.
• 20. Regeneron Pharmaceuticals, Inc.
• 21. Samyang Holdings Corporation
• 22. Sanofi S.A.
• 23. Takeda Pharmaceutical Company Limited
• 24. Teva Pharmaceutical Industries Ltd.
• 25. Turnstone Biologics